Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation

Journal of Cellular Physiology

Volumn 186, Issue 1, 2001, Pages 1-10

  Koyama, Hidenori ^a   Bornfeldt, Karin E ^b   Fukumoto, Shinya ^a   Nishizawa, Yoshiki ^a  

^a School of Medicine   (Japan)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; CYCLIC NUCLEOTIDE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; GUANYLATE CYCLASE;

APOPTOSIS; ARTERY MUSCLE; CELL CYCLE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME SPECIFICITY; MITOGENESIS; PRIORITY JOURNAL; REVIEW; SECOND MESSENGER; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY;

ANIMALS; CELL DIVISION; HUMANS; MITOSIS; MUSCLE, SMOOTH, VASCULAR; NUCLEOTIDES, CYCLIC; PHOSPHORIC DIESTER HYDROLASES; SIGNAL TRANSDUCTION;

EID: 0035196047     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-4652(200101)186:1<1::AID-JCP1012>3.0.CO;2-D     Document Type: Review

References (115)

1. Atrial natriuretic factor inhibits proliferation of vascular smooth muscle cells stimulated by platelet-derived growth factor
2. 2+ mobilization, by cyclic AMP and GMP in rabbit aortic smooth-muscle cells
3. TGF-beta 1 and cAMP attenuate cyclin A gene transcription via a cAMP responsive element through independent pathways
4. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms
5. Nitric oxide donors selectively potentiate thrombin-stimulated p70(S6k) activity and morphological changes in Swiss 3T3 cells
6. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants
7. Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene
8. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction
9. Crosstalk between protein kinase A and growth factor receptor signaling pathways in arterial smooth muscle
10. Nitric oxide and C-type atrial natriuretic peptide stimulate primary aortic smooth muscle cell migration via a cGMP-dependent mechanism: Relationship to microfilament dissociation and altered cell morphology
11. Inhibition of the phosphatidylinositol 3-kinase/p70(S6)-kinase pathway induces B16 melanoma cell differentiation
12. Critical binding and regulatory interactions between Ras and Raf occur through a small, stable N-terminal domain of Raf and specific Ras effector residues
13. Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1
14. Recent progress in understanding the hormonal regulation of phosphodiesterases
15. Inhibition by cAMP of Ras-dependent activation of Raf
16. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP
17. 2+ by atriopeptin and 8-bromo-cyclic GMP is mediated by cyclic GMP-dependent protein kinase
18. Differential regulation of extracellular signal-regulated protein kinases (ERKs) 1 and 2 by cAMP and dissociation of ERK inhibition from anti-mitogenic effects in rabbit vascular smooth muscle cells
19. Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs
20. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP
21. Protein kinase A anchoring
22. Guanylate cyclase and the NO/cGMP signaling pathway
23. Atrial and C-type natriuretic peptides amplify growth factor activity in primary aortic smooth muscle cells
24. NO increases protein tyrosine phosphatase activity in smooth muscle cells: Relationship to antimitogenesis
25. Ribosomal S6 kinase signaling and the control of translation
26. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A
27. Signal transduction. The hunt for Ras targets
28. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase
29. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase
30. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)
31. Distinct role of cAMP and cGMP in the cell cycle control of vascular smooth muscle cells: cGMP delays cell cycle transition through suppression of cyclin D1 and cyclin-dependent kinase 4 activation
32. C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells
33. Inhibition of G1 cyclin expression and G1 cyclin-dependent protein kinases by cAMP in an astrocytic cell line
34. The guanylyl cyclase receptors
35. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells
36. cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells
37. Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells
38. Insulin, growth factors, and cAMP
39. Nitric oxide-induced increase in p21(Sdi1/Cip1/Waf1) expression during the cell cycle in aortic adventitial fibroblasts
40. Nitric oxide increases p21(Waf1/Cip1) expression by a cGMP-dependent pathway that includes activation of extracellular signal-regulated kinase and p70(S6k)
41. Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene (PDE9A) that maps to 21q22.3: Alternative splicing of mRNA transcripts, genomic structure and sequence
42. Role of adenylyl cyclase in proliferation of neonatal pulmonary artery smooth muscle cells
43. Mechanism of inhibition of Raf-1 by protein kinase A
44. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D
45. Nitric oxide selectively amplifies FGF-2-induced mitogenesis in primary rat aortic smooth muscle cells
46. The adenylyl and guanylyl cyclase superfamily
47. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury
48. Induction of the cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1) by nitric oxide-generating vasodilator in vascular smooth muscle cells
49. Tumor suppressor p53 but not cGMP mediates NO-induced expression of p21(Waf1/Cip1/Sdi1) in vascular smooth muscle cells
50. The adenylyl cyclases as integrators of transmembrane signal transduction
51. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats
52. PDGF induces an early and a late wave of PI 3-kinase activity, and only the late wave is required for progression through G1
53. Antiproliferative action of cyclic GMP-elevating vasodilators in cultured rabbit aortic smooth muscle cells
54. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation
55. A family of cAMP-binding proteins that directly activate Rap1
56. Activation of mitogen-activated protein kinase pathways by cyclic GMP and cyclic GMP-dependent protein kinase in contractile vascular smooth muscle cells
57. The fumagillin analogue TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-I. Possible involvement of cyclin-dependent kinase 2
58. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors
59. Growth-inhibitory effect of cyclic GMP- and cyclic AMP-dependent vasodilators on rat vascular smooth muscle cells: Effect on cell cycle and cyclin expression
60. Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways: A potential mechanism allowing for the coordinated regulation of PDE4D activity and expression in cells
61. Distinct and specific functions of cGMP-dependent protein kinases
62. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',-5'-cyclic nucleotide phosphodiesterase
63. Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase
64. Type III cyclic nucleotide phosphodiesterases and insulin action
65. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B
66. cAMP-mediated growth inhibition in fibroblasts is not mediated via mitogen-activated protein (MAP) kinase (ERK) inhibition. cAMP-dependent protein kinase induces a temporal shift in growth factor-stimulated MAP kinases
67. Control of pRB phosphorylation
68. Activation of pp70/85 S6 kinases in interleukin-2-responsive lymphoid cells is mediated by phosphatidylinositol 3-kinase and inhibited by cyclic AMP
69. The 1996 Albert Lasker Medical Research Awards. Signal transduction using nitric oxide and cyclic guanosine monophosphate
70. Inhibition by nitric oxide and nitric oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cells
71. E2F: A link between the Rb tumor suppressor protein and viral oncoproteins
72. Multiple splice variants of phosphodiesterase PDE4C cloned from human lung and testis
73. Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: Implications for phosphodiesterase 3 inhibition in human cardiovascular tissues
74. cGMP accumulation and gene expression of soluble guanylate cyclase in human vascular tissue
75. The guanine nucleotide exchange factor CNrasGEF activates ras in response to cAMP and cGMP
76. Phosphatidylinositol 3-kinase activity regulates alpha-thrombin-stimulated G1 progression by its effect on cyclin D1 expression and cyclin-dependent kinase 4 activity
77. Redistribution of the CDK inhibitor p27 between different cyclin. CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation
78. Isolation and characterization of human cDNAs encoding a cGMP-stimulated 3',5'-cyclic nucleotide phosphodiesterase
79. The pathogenesis of atherosclerosis: A perspective for the 1990s
80. Cyclic GMP-dependent protein kinases: Understanding in vivo functions by gene targeting
81. Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation
82. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype
83. Differential expression of the cyclic GMP-stimulated phosphodiesterase PDE2A in human venous and capillary endothelial cells
84. Cyclic nucleotide-dependent protein kinases
85. A regulatory role for cAMP in phosphatidylinositol 3-kinase/p70 ribosomal S6 kinase-mediated DNA synthesis in platelet-derived-growth-factor-stimulated bovine airway smooth-muscle cells
86. Attenuation of mammalian target of rapamycin activity by increased cAMP in 3T3-L1 adipocytes
87. Increasing cAMP attenuates activation of mitogen-activated protein kinase
88. Human cyclin D1 encodes a labile nuclear protein whose synthesis is directly induced by growth factors and suppressed by cyclic AMP
89. Mammalian G1 cyclins
90. CDK inhibitors: Positive and negative regulators of G1-phase progression
91. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase
92. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases
93. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A
94. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions
95. Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP
96. Parathyroid hormone-related protein induces G1 phase growth arrest of vascular smooth muscle cells
97. Cyclic-GMP-dependent protein kinase inhibits the Ras/mitogen-activated protein kinase pathway
98. Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70(S6K)-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts
99. Nitric oxide modulates expression of cell cycle regulatory proteins: A cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation
100. cAMP-dependent protein kinase: Framework for a diverse family of regulatory enzymes
101. Protein kinases as mediators of phosphoinositide 3-kinase signaling
102. Local expression of C-type natriuretic peptide markedly suppresses neointimal formation in rat injured arteries through an autocrine/paracrine loop
103. Signalling by cGMP-dependent protein kinases
104. G1 phase arrest of human smooth muscle cells by heparin, IL-4 and cAMP is linked to repression of cyclin D1 and cdk2
105. Signaling by distinct classes of phosphoinositide 3-kinases
106. Identification of cGMP-dependent protein kinase anchoring proteins (GKAPs)
107. Multiple pathway signal transduction by the cAMP-dependent protein kinase
108. cAMP pulse during preservation inhibits the late development of cardiac isograft and allograft vasculopathy
109. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3',5'-monophosphate
110. ANF elicits phosphorylation of the cGMP phosphodiesterase in vascular smooth muscle cells
111. Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene
112. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway
113. Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression
114. Binding and phosphorylation of a novel male germ cell-specific cGMP-dependent protein kinase-anchoring protein by cGMP-dependent protein kinase Ialpha
115. Adenylyl cyclase isoforms and vasopressin enhancement of agonist-stimulated cAMP in vascular smooth muscle cells